• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Parasitic worms
      • Mycetoma
      • Dengue
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Evidence for impact
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi West and Central Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • Our story
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

DNDi delivers statement about CEWG on R&D Financing and Coordination at 69th World Health Assembly

Home > News

DNDi delivers statement about CEWG on R&D Financing and Coordination at 69th World Health Assembly

World Health Assembly 2016
27 May 2016

At the 69th World Health Assembly, Member States were asked to consider the outcomes of the Open-Ended Meeting and continue discussions on issues related to monitoring, coordination and financing for health research.

Michelle Childs, DNDi‘s Head of Policy Advocacy, delivered the following statement on behalf of DNDi.

“The main system driving and financing medical innovation is failing to deliver on many fronts. R&D is lacking for Neglected Tropical Diseases, emerging infectious diseases, antimicrobial resistance; Access to Hepatitis treatment is rationed.

DNDi’s portfolio has expanded beyond an NTD focus (including the demonstration project for leishmaniasis) to reflect this.

Innovation and access are on the political agenda like never before, but the response to these failures is fragmented. At this assembly multiple agenda items propose R&D frameworks.

Different frameworks for different diseases fail to address 5  core problems:

  1. No global body to identify R&D needs,
  2. No globally-agreed priority setting,
  3. No coordination of R&D efforts to reduce duplication,
  4. Lack of sustainable financing,
  5. No globally-agreed norms that guide R&D initiatives to ensure affordability

This agenda item presents an opportunity to consider a common core framework and the elements within it.

DNDi’s model is based on open innovation, de-linkage, and affordable access. Based on our experience, we urge Member States to consider 4 actions to enable the emergence of a more sustainable and efficient innovation system:

  1. Request WHO to establish a process for priority setting for all areas of public health importance;
  2. ensure the Global Observatory is sustainably funded and covers all areas of public health importance;
  3. ensure pooled funds cover all areas of need, focus on agreed priorities and apply the CEWG principles of innovation with access including de-linkage;
  4. join the dots between multiple frameworks and progressively  develop an overarching framework for all R&D actors and all areas of public health importance.  Including  WHO  engaging  in other policy fora to promote the implementation of the CEWG principles.

Member States should ask WHO to organize an intergovernmental conference on policy coherence for R&D, to consider core common elements for development of global frameworks for R&D.”

Read, watch, share

Loading...
MASAMUNA, DR CONGO, JANUARY 2026: The mother superior of the nuns who run the local clinic is also the lab technican.
Press releases
12 Jun 2026

DRC approves the use of acoziborole, a breakthrough one-day oral treatment against sleeping sickness 

Statements
9 Jun 2026

DNDi Statement at the UN Multi-Stakeholder Hearing on Pandemic Prevention, Preparedness, and Response (PPPR)

Press releases
8 Jun 2026

DNDi, GARDP, and MMV join forces to accelerate drug development for patients in greatest need

Statements
19 May 2026

DNDi interventions at the 79th World Health Assembly

Dr Sergio Sosa-Estani
Statements
15 May 2026

DNDi statement on hantavirus outbreak: ‘Investment in pandemic preparedness efforts remains insufficient.’

Statements
13 May 2026

DNDi’s briefing note for 79th World Health Assembly

Close up of legs with sandals on a dry soil
Press releases
12 May 2026

DNDi welcomes GHIT support for global evaluation and registration of fosravuconazole for eumycetoma, in collaboration with Eisai

Press releases
27 Apr 2026

Thailand registers ravidasvir, a simple-to-use and effective antiviral for hepatitis C, expanding treatment options for Thai patients

VIEW ALL

Help neglected patients

To date, we have delivered fourteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Youtube X-twitter Tiktok Facebook-f
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films, and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license